MA32955B1 - Combinaison antitumorale associant l'ave8062 et le docetaxel - Google Patents

Combinaison antitumorale associant l'ave8062 et le docetaxel

Info

Publication number
MA32955B1
MA32955B1 MA34002A MA34002A MA32955B1 MA 32955 B1 MA32955 B1 MA 32955B1 MA 34002 A MA34002 A MA 34002A MA 34002 A MA34002 A MA 34002A MA 32955 B1 MA32955 B1 MA 32955B1
Authority
MA
Morocco
Prior art keywords
ave8062
docetaxel
combines
tumor combination
combination
Prior art date
Application number
MA34002A
Other languages
Arabic (ar)
English (en)
Inventor
Michèle Besenval
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32955(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA32955B1 publication Critical patent/MA32955B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L' INVENTION EST RELATIVE À UNE COMBINAISON ANTITUMORALE ET SÉQUENTIELLE D'AVE8062 OU D'UN SEL D'AVE8062 ET DE DOCETAXEL CARACTÉRISÉE EN CE QUE 1?VE8062 EST ADMINISTRÉ À UN PATIENT À UNE DOSE COMPRISE ENTRE 10 ET 50 MG/M2 PUIS UN JOUR DIFFÉRENT DE LA SEMAINE, DE PRÉFÉRENCE APRÈS UN INTERVALLE DE 24 HEURES, LE DOCETAXEL À UNE DOSE COMPRISE ENTRE 50 ET 120 MG/M2.
MA34002A 2008-12-12 2009-12-10 Combinaison antitumorale associant l'ave8062 et le docetaxel MA32955B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0806979A FR2939665B1 (fr) 2008-12-12 2008-12-12 Combinaison antitumorale associant l'ave8062a et le docetaxel
PCT/FR2009/052475 WO2010067027A1 (fr) 2008-12-12 2009-12-10 Combinaison antitumorale associant l'ave8062 et le docetaxel

Publications (1)

Publication Number Publication Date
MA32955B1 true MA32955B1 (fr) 2012-01-02

Family

ID=40790630

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34002A MA32955B1 (fr) 2008-12-12 2009-12-10 Combinaison antitumorale associant l'ave8062 et le docetaxel

Country Status (27)

Country Link
US (1) US20120004294A1 (fr)
EP (1) EP2376076A1 (fr)
JP (1) JP2012511554A (fr)
KR (1) KR20110104932A (fr)
CN (1) CN102245175A (fr)
AR (1) AR074599A1 (fr)
AU (1) AU2009326220A1 (fr)
BR (1) BRPI0923349A2 (fr)
CA (1) CA2746475A1 (fr)
CL (1) CL2011001316A1 (fr)
CO (1) CO6390037A2 (fr)
CR (1) CR20110319A (fr)
EA (1) EA201170803A1 (fr)
EC (1) ECSP11011112A (fr)
FR (1) FR2939665B1 (fr)
IL (1) IL213458A0 (fr)
MA (1) MA32955B1 (fr)
MX (1) MX2011006253A (fr)
NI (1) NI201100114A (fr)
PA (1) PA8853301A1 (fr)
PE (1) PE20120125A1 (fr)
SG (1) SG172071A1 (fr)
TN (1) TN2011000268A1 (fr)
TW (1) TW201032798A (fr)
UY (1) UY32318A (fr)
WO (1) WO2010067027A1 (fr)
ZA (1) ZA201104358B (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
JP2004523517A (ja) 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法
US20050209310A1 (en) 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines

Also Published As

Publication number Publication date
MX2011006253A (es) 2011-11-04
CR20110319A (es) 2011-09-20
TN2011000268A1 (fr) 2012-12-17
TW201032798A (en) 2010-09-16
JP2012511554A (ja) 2012-05-24
WO2010067027A1 (fr) 2010-06-17
SG172071A1 (en) 2011-07-28
PA8853301A1 (es) 2010-07-27
PE20120125A1 (es) 2012-02-23
BRPI0923349A2 (pt) 2015-07-21
CA2746475A1 (fr) 2010-06-17
AU2009326220A1 (en) 2011-07-07
ECSP11011112A (es) 2011-07-29
EP2376076A1 (fr) 2011-10-19
UY32318A (es) 2010-07-30
AR074599A1 (es) 2011-01-26
CO6390037A2 (es) 2012-02-29
CN102245175A (zh) 2011-11-16
EA201170803A1 (ru) 2011-12-30
FR2939665B1 (fr) 2011-10-07
NI201100114A (es) 2011-12-13
ZA201104358B (en) 2012-09-26
KR20110104932A (ko) 2011-09-23
US20120004294A1 (en) 2012-01-05
CL2011001316A1 (es) 2011-10-28
FR2939665A1 (fr) 2010-06-18
IL213458A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
MX2009008825A (es) Nuevos metodos de terapia anticolinergica.
TW200738269A (en) Oral delivery of therapeutic agents using tight junction agonists
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
BR112021024886A2 (pt) Métodos de tratar a doença de fabry em pacientes com insuficiência renal
BR112015014095A2 (pt) entrega transmucosal de acetato de glatirâmero
CY1117831T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη του καρκινου του μαστου
AR081925A1 (es) Uso de ranolazina para el tratamiento de la hipertension pulmonar
MA32955B1 (fr) Combinaison antitumorale associant l'ave8062 et le docetaxel
ATE489399T1 (de) Antitumor wirksame 2-substituierte estra-1,3, 5(10)-trien-3-yl sulfamate
ATE546133T1 (de) Orale dosierform mit trisubstituierten glycerin- verbindungen
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.
TR200904341A2 (tr) Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
Calderon Cabrera Bexarotene/cyclophosphamide/pentostatin
AR053855A1 (es) Metodo para la administracion de capecitabina
CY1120970T1 (el) Φαρμακευτικη μορφη δοσολογιας που περιλαμβανει 6'-φθορο-(ν-μεθυλ-ή ν,ν-διμεθυλ-)-4-φαινυλ-4',9'-διυδρο-3ή-σπeipo[kykλoeξano-1,1'-πυρano[3,4,b]inδoλ]-4-aminh για την αγωγη του αλγαισθητικου πονου
Cran Hydromorphone/oxycodone
BR112021018896A2 (pt) Composição de liberação sustentada compreendendo oxalato de tapentadol e método de preparação do mesmo
Prodduturi Bone marrow aplasia: case report